On Wednesday, OS Therapies, Inc. OSTX revealed knowledge from a Part 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate within the uncommon pediatric-designated indication of prevention of recurrent, totally resected, lung metastatic osteosarcoma, a uncommon, cancerous bone tumor that develops in bone-forming cells.
The information display statistically important leads to the first endpoint of the research, 12-month event-free survival (EFS), the place an occasion is outlined because the recurrence of metastatic osteosarcoma, in OST-HER2-treated sufferers compared with the printed historic comparable management group.
Additional, as of the latest follow-up, the info present a robust pattern in favor of OST-HER2-treated sufferers in total survival (‘OS,’ remaining alive) on the 1-year and 2-year interim time factors of the continuing 3-year total survival secondary endpoint.
Notably, all sufferers who achieved the first 12-month EFS endpoint stay alive.
“We’re extraordinarily happy with these outcomes of our Part 2b medical trial as a result of they present that OST-HER2-treated sufferers achieved the first endpoint of 12-month EFS in a statistically considerably larger ratio than comparable historic controls, along with rising the chance of 1-year and 2-year survival as in contrast with comparable historic controls,” commented Robert Petit, Chief Medical & Scientific Officer of OS Therapies.
Major Endpoint of 12-month EFS:
- 33% for OST-HER2 vs. 20% for historic management (p=0.0158)
Interim Evaluation of Ongoing Secondary Endpoint, General Survival:
- 1-year: 91% for OST-HER2 vs. 80% for historic management (p=0.07) and 61% vs. 40% for 2-year (p = 0.0576).
Just lately, OS Therapies closed a non-public placement financing, elevating roughly $6 million in gross proceeds.
The corporate will use the proceeds for working capital, totally on medical and regulatory milestones, to assist the commercialization of its lead therapeutic candidate, OST-HER2.
Worth Motion: OSTX inventory is up 7.96% at $4.49 finally test Wednesday.
Learn Subsequent:
Picture by way of Shutterstock.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
